Clinical trialPhase 1Terminated
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
- Outcome
- Stopped earlyThe trial has been terminated earlier following the company decision to discontinue the clinical development of Evofosfamide (Business decision)
- Phase
- Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- January 2014
- Expected end
- May 2016
- Enrollment
- 19 participants
- Sites
- 5
- Primary outcomes
- Number of Subjects Experiencing Dose Limiting Toxicity (DLT)
- Sponsor
- Industry
- Results posted
- 2017-12-15
- Last update
- 11 May 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Subjects Experiencing Dose Limiting Toxicity (DLT) [Up to Day 28 of Cycle 1]. Count Of Participants, Participants. TH-302 Plus Nab-paclitaxel Plus Gemcitabine (n=18): 1.